Tanox was a biopharmaceutical company based in Houston, Texas. The company was founded by two biomedical research scientists, Nancy T. Chang and Tse Wen Chang in March 1986 with $250,000, which was a large part of their family savings at that time.

Talizumab (TNX-901) is a humanized monoclonal antibody that was under development by Tanox in Houston, Texas as a new-concept therapeutic for allergic diseases.

2007年8月3日 · Genentech Inc. said Thursday that it has completed the $919 million acquisition of Tanox Inc., its partner in the development of the asthma drug Xolair, with the expiration of a waiting period...

2007年1月16日 · Tanox’s lead investigational therapy, TNX-355, is a viral-entry inhibitor antibody to treat HIV/AIDS. TNX-355 has shown significant antiviral activity in Phase 2 clinical testing. Tanox’s first-approved drug, Xolair (R) (omalizumab), is the first antibody approved to treat moderate-to-severe confirmed, allergic asthma.

Tanox, Inc. is a a biotechnology company, engages in the discovery and development of therapeutic monoclonal antibodies.

Tanox is a biotechnology company specializing in the development of monoclonal antibodies. The company develops innovative biotherapeutics for the treatment of immune-mediated diseases, inflammation, infectious disease and cancer.

2018年12月15日 · Tanox, Inc. is a biotechnology company engaged in the development of monoclonal antibodies that treat unmet medical needs related to asthma, allergy, inflammation, autoimmune disease, and other conditions stemming from an overactive immune system.

2007年8月3日 · Genentech says it has completed its $919 million acquisition of US monoclonal antibody specialist Tanox, which gives the biotechnology gaining access to several drugs, notably the asthma treatment Xolair.

Genentech, Novartis and Tanox have co-developed Genentech's anti-IgE humanized monoclonal antibody omalizumab for the treatment of allergic rhinitis and asthma. The antibody is currently undergoing phase II clinical trials for allergic rhinitis in Canada and …

2006年11月9日 · Genentech, Inc. and Tanox, Inc. today announced plans for Genentech to acquire Tanox, a biotechnology company specializing in the discovery and development of biotherapeutics based on monoclonal...